Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy

European Journal of Pharmacology

Volumn 569, Issue 1-2, 2007, Pages 126-137

  Chuang, Yen Hwang ^a   Chuang, Wan Long ^a   Huang, Shu Pin ^a   Huang, Chun Hsiung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

COX 2; COX 2 inhibitor; Obstructive uropathy; TGF ; Ureter

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CELECOXIB; CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HYDROURETER; NONHUMAN; OBSTRUCTIVE UROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE; TREATMENT DURATION; URETER DISEASE; URETER FIBROSIS; URETER LIGATION;

ACTINS; ANIMALS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDRONEPHROSIS; IMMUNOHISTOCHEMISTRY; LIGATION; MUSCLE, SMOOTH; ORGAN SIZE; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; URETER; URETERAL OBSTRUCTION; URETHRAL DISEASES;

EID: 34547598803     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.04.046     Document Type: Article

References (39)

1. Alvarez-Soria M.A., Large R., Santillana L.R., Sanchez-Pernaute O., Calvo E., Hernandez M., Egido J., and Herrero-Beaumont G. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann. Rheum. Dis. 65 (2006) 998-1005
2. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., and Taubert K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American heart association. Circulation 115 (2007) 1634-1642
3. Bonazzi A., Mastyugin V., Mieyal P.A., Dunn M.W., and Laniado-Schwartzman M. Regulation of Cyclooxygenase-2 by hypoxia and peroxisome proliferation in the corneal epithelium. J. Biol. Chem. 275 (2000) 2837-2844
4. Border W.A., and Nobel N.A. Transforming growth factor-β in tissue fibrosis. N. Engl. J. Med. 10 (1994) 1286-1292
5. Chuang Y.H., Chuang W.L., Liu K.M., Chen S.S., and Huang C.H. Tissue damage and regeneration of the ureteric smooth muscle in rat with obstructive uropathy. Br. J. Urol. 82 (1998) 261-266
6. Chuang Y.H., Chuang W.L., Chen S.S., and Huang C.H. Expression of transforming growth factor-β1 and its receptors related to the ureteric fibrosis in a rat model of obstructive uropathy. J. Urol. 163 (2000) 1298-1303
7. Chuang Y.H., Chuang W.L., and Huang C.H. Myocyte apoptosis in the pathogenesis of ureteral damage in rats with obstructive uropathy. Urology 58 (2001) 463-470
8. Clemett D., and Goa K.L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis, and acute pain. Drug 59 (2000) 957-980
9. Cuzzocrea S., Mazzon E., Serraino I., Dugo L., Centorrino T., Ciccolo A., Sautebin L., and Caputi A.P. Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur. J. Pharmacol. 431 (2001) 91-102
10. FitzGerald G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351 (2004) 1709-1711
11. Gulmi F.A., Felsen D., and Vaughan E.D. The pathophysiology of urinary tract obstruction. In: Walsh P.C., Retik A.B., Vaughan E.D., and Wein A.J. (Eds). Campbell's Urology (2002), WB Saunders, Philadelphia 411-456
12. Hinz B., and Brune K. Cyclooxygenase-2-10 years late. J. Pharmacol. Exp. Ther. 300 (2002) 367-375
13. Hu K.Q. Cyclooxygenase-2 (COX-2)-prostanoid pathway and liver diseases. Prostaglandins Leukot. Essent. 69 (2003) 329-337
14. Heyman S.N., Fuchs S., Jaffe R., Shina A., Ellezian L., Brezis M., and Rosen S. Renal microcirculation and tissue damage during acute ureteral obstruction in the rat: effect of saline infusion, indomethacin and radiocontrast. Kidney Int. 51 (1997) 653-663
15. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., and Smulson M.E. Induction of apoptosis in proliferation human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58 (1998) 4510-4514
16. Kaplan-Machlis B., and Klostermeyer B.S. The cyclooxygenase-2 inhibitors: safety and effectiveness. Ann. Pharmacother. 33 (1999) 979-988
17. Keerthisingam C.B., Jenkins R.G., Harrison N.K., Hernandez-Rodriguez N.A., Booth H., Laurent G.J., Hart S.L., Foster M.L., and Mcanulty R.J. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferation response to transforming growth factor-1 in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 154 (2001) 1411-1422
18. LaPointe M.C., Mendez M., Leung A., Tao Z., and Yang X.P. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1416-H1424
19. Leahy A.L., Ryan P.C., McEnttee G.M., Nelson A.C., and Fitzpatrick J.M. Renal injury and recovery in partial ureteric obstruction. J. Urol. 142 (1989) 199-203
20. Malmstrom J., Lindberg H., Lindberg C., Bratt C., Wieslander E., Delander E.L., Sarnstrand B., Burns J.S., Mose-Larsen P., Fey S., and Marko-Varga G. Transforming growth factor-beta 1 specifically induce proteins involved in the myofibroblast contractile apparatus. Mol. Cell Proteomics 3 (2004) 466-477
21. Mastbergen S.C., Lafeber F.P.J.G., and Bijlsma J.W.J. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology 41 (2002) 801-808
22. Miyajima A., Chen J., Lawarence C., Ledbetter S., Sosolow R.A., Stern J., Jha S., Pigato J., Lemer M.L., Poppas D.P., Vaughan D., and Felsen D. Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int. 58 (2000) 2301-2313
23. Miyajima A., Asano T., Asano T., Yoshimura I., Seta K., and Hayakawa M. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction. J. Urol. 165 (2001) 1714-1718
24. Miyajima A., Ito K., Asano T., Seta K., Ueda A., and Hayakawa M. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction. J. Urol. 166 (2001) 1124-1129
25. Nakada S.Y., Jerde T.J., Jacobson L.Y., Saban R., Bjorling D.E., and Huliett D.A. Cyclooxygenase-2 expression is up-regulated in obstructed human ureter. J. Urol. 168 (2002) 1226-1229
26. Narayanan B.A., Narayanan N.K., Pttman B., and Reddy B.S. Adenocarcinoma of the mouse prostate growth inhibition by Celecoxib: downregulation of transcription factors involved in COX-2 inhibition. Prostate 66 (2006) 257-265
27. Norregaard R., Jensen B.L., Topcu S.O., Nielsen S.S., Walter S., Djurhuus J.C., and Frokiaer J. Cyclooxygenase type 2 is increased in obstructed rat and human ureter and contributes to pelvic pressure increase after obstruction. Kidney Int. 70 (2006) 872-881
28. Park J.M., Yang T., Arend L.J., Schinermann J.B., Peters C.A., Freeman M.R., and Briggs J.P. Obstruction stimulates Cox-2 expression in bladder smooth muscle cells via increased mechanical stretch. Am. J. Physiol. 276 (1999) F129-F136
29. Planaguma A., Claria J., Miquel R., Lopez-Parra M., Titos E., Masferrer J.L., Arroyo V., and Rodes J. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARγ activation. FASEB J. 19 (2005) 1120-1122
30. Reddy B.S., Patlolla J.M., Simi B., Wang S.H., and Rao C.V. Prevention of colon cancer by low doses of Celecoxib, a cyclooxygenase inhibitor, administered in diet rich in ω-3 polyunsaturated fatty acids. Cancer Res. 65 (2005) 8022-8027
31. Sasaki T., Kitagawa K., Yamagata K., Tanaka S., Pmura-Matsuoka E., Sugiura S., Matsumoto M., and Hori M. Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J. Cereb. Blood Flow Metab. 24 (2004) 107-113
32. Serini G., and Gabbiani G. Mechanisms of myofibroblast activity and phenotype modulation. Exp. Cell Res. 250 (1999) 273-283
33. Smith W.L., Dewitt D.L., and Garavito R.M. Cyclooxygenase: structure, cellular, and molecular biology. Ann. Rev. Biochem. 69 (2000) 145-182
34. min mice. Cancer Res. 66 (2006) 7370-7377
35. Turini M.E., and Dubois R.N. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. 53 (2002) 35-57
36. Wang X.L., Liu S.X., and Wilcken D.E.L. Circulating transforming growth factor 1 and coronary artery disease. Cardiovasc. Res. 34 (1997) 404-410
37. Williams G.T., and Smith C.A. Molecular regulation of apoptosis: genetic controls on cell death. Cell 74 (1993) 777-779
38. Yu C.C.-W., and Filipe M.I. Update on proliferation-associated antibodies applicable formalin-fixed paraffin-embedded tissue and their clinical applications. Histochem. J. 25 (1993) 843-853
39. Zoppo G.D., Ginis I., Hallenbeck J.M., Ladecola C., Wang X., and Feuerstein G.Z. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10 (2000) 95-112